The prevalence, awareness, treatment and control of dyslipidemia among adults in China

Objectives: To analyze the prevalence, awareness, treatment, control and epidemiological characteristics of dyslipidemia in Chinese adults. Methods: In this cross-sectional study, we adopted a multi-stage, stratified sampling method to obtain representative samples of the general population aged >18 years from different urban and rural regions in China. All subjects completed a lifestyle and medical history questionnaire and were examined for risk factors. Dyslipidemia was defined according to criteria of the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Continuous variables were compared using variance analysis. Multivariate logistic regression analysis was performed to explore the risk factors of dyslipidemia. Results: The prevalence of dyslipidemia was 34.0% overall, and 35.1%, and 26.3% in urban and rural areas, respectively. The prevalence of dyslipidemia was significantly higher in men than women (41.9% vs 32.5%; P < 0.001). Rates of awareness, treatment, and control were 31.0%, 19.5%, and 8.9%, respectively. Increasing age (OR = 1.012; 95% CI: 1.010, 1.014), male sex (OR = 1.411; 95% CI: 1.318, 1.510), obesity (OR = 1.424; 95% CI: 1.345, 1.507), cardiovascular disease (OR = 1.343; 95% CI: 1.125, 1.603), diabetes (OR = 1.955; 95% CI: 1.751, 2.182), hypertension (OR = 1.481; 95% CI: 1.391, 1.577) and hyperuricemia (OR = 2.223; 95% CI: 2.060, 2.399) were independent risk factors of dyslipidemia. Conclusion: The prevalence of dyslipidemia among Chinese adults was high but awareness, treatment, and control of dyslipidemia were low. Urban high income earners and rural medium income earners show higher prevalence. Low income earners in urban and rural population have the worst awareness treatment, and control rate. There is an increased need for closely monitoring and controlling high risk factors in the populations including postmenopausal women, unhealthy lifestyle peoples and patients with chronic non-communicable diseases. (C) 2016 Elsevier Ireland Ltd. All rights reserved.